SAM
MRTX

Silphium Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Silphium Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,687
Closed -$280K – 157
2018
Q2 		$280K Buy
+5,687
New +$215K 0.09% 77

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Silphium Asset Management's MRTX Position: Q3 2018 in Review

Silphium Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2018, closing a stake of 5,687 shares — an estimated $280K sold.

Silphium Asset Management first reported a position in MRTX in Q2 2018 and held it in 1 quarter. The position peaked at $280K in Q2 2018. 125 funds tracked by Wall St. Rank hold MRTX as of Q3 2018.

  • Silphium Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Silphium Asset Management sold 5,687 Mirati Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $280K.
  • Silphium Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Silphium Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $280K in Q2 2018.
  • 125 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Silphium Asset Management's 13F filing for Q3 2018, filed 30 Jan 2025.